Holger A. Russ
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Tumor analysis in mHM and mHM TA . A, Comparison of the average mouse tumor burden on mHM ( n = 27 on nine mice) and mHM TA ( n = 30 on 10 mice) shows that PDX growth on mHM TA is significantly slowed ( P = 0.007, linear mixed-effects model). B, Comparison of tumor volumes also indicates slower PDX growth in mHM TA ( P = 0.003, linear mixed-effects model). For A and B , the marginal fit plus the residuals are plotted for each mouse/tumor at each timepoint are shown as circles. C, PFS (defined as a 20% increase in volume from the starting date) analysis of mHM and mHM TA tumors ( P = 0.0006, cumulative HR). D, Ki67 IHC staining of mHM and mHMTA tumors showing the depth of thickness of living cells surrounding the necrotic tumor core. Magnification is 5×; scales bar, 100 μm. E, Quantification of the depth of these proliferating cells from the tumor edge ( P = 0.048, two-group t test). F, Normalized comparison of mHM and mHM TA tumor volumes reveals a significant reduction in mHM TA ( P = 0.019, two-group t test). G, Likewise, a normalized comparison of mHM and mHM TA live tumor volumes indicates a significant reduction in mHM TA ( P = 0.034, two-group t test). H, A comparison of human CD45 + cell infiltration in the tumors of mHM and mHM TA ( P = 0.743, Wilcoxon rank-sum test). I, A comparison of T-cell infiltration in mHM and mHM TA tumors ( P = 0.468, Wilcoxon rank-sum test). J, IHC of CD3/45+ T cells (indicated by arrows) infiltrating the mHM and mHM TA tumors. Magnification is 40×; scale bar, 50 μm. K, Quantification of human CD45 + lymphocytes within the tumor tissue and capsule indicates increased infiltration within mHM TA tumors ( P = 0.0207, Wilcoxon rank-sum test). L, Quantification of human CD3 + T cells within the tumor tissue and capsule likewise revealed increased infiltration in mHM TA tumors ( P = 0.0107, Wilcoxon rank-sum test). P values: *, ≤0.05; **, ≤0.01; ***, ≤0.001. huCD3, human CD3; huCD45, human CD45.
Year:
2025
In vivo sTO characterization. A, Overview of mHM TA production. Tumor biopsies are implanted as PDXs on NSG mice to expand prior to use in the HM. Patient blood is also drawn at the time of biopsy and reprogrammed into iPSCs and subsequent sTOs, using HLA-A –matched cord blood–derived HSPCs. The sTOs are surgically implanted into the kidney capsule of thymectomized mHM produced with the same HSPCs used to produce the mHM TA . After human peripheral blood cells have been identified in the HM, PDX tissue is implanted into the mHM and mHM TA . B, Picture of a successfully engrafted sTO growing under the kidney capsule, indicated by the yellow arrow. Scale bar, 1 mm. C, Top row (inset): IHC comparison of human thymic tissue with engrafted sTO tissue shows that the sTO tissue expresses both human KRT5 and KRT8. Magnification is 10×; scale bar, 100 ×m. Middle row: Magnified portion of the boxed region in the above sTOs. Columns 1–2, magnification is 20×; scale bar, 50 ×m. Column 3, magnification is 40×; scale bar, 25 μm. Bottom row: Human thymus, for comparison. Magnification is 20×; scale bar, 50 μm. H&E, hematoxylin and eosin. D, Cytometry with all gating of a successfully engrafted sTO shows that the tissue harbors CD4/8 DP T cells undergoing thymic selection and maturation. IHC dual staining of engrafted sTO tissue shows that the tissue harbors CD4/8 DP T cells undergoing thymic selection and maturation. Magnification = 40×; scale bar, 25 μm). Cytometry shows that the tissue harbors CD4/8 DP T cells undergoing thymic selection and maturation. E, MIBI images of an engrafted sTO show that the cellular tissue expresses pan-keratin and ki67, markers of viability. The presence of human CD45 + cells, as well as the expression of HLA class I and HLA-DR proteins, shows its role in immune cell education. F, MIBI images of the sTO also show thymus-specific protein expression. Top row: IDO-1, podoplanin, T-bet, and Tim3. Their merged expression is shown in the final image. Bottom row: Images of sTO-associated T cells, initially showing an overview of the sTO and subsequently an example of a CD3/4+ T cell enlarged in images. The final image is of a nongrafted mouse kidney for comparison of all markers. White scale bar, 100 μm. Red scale bar, 25 μm.
Year:
2025
A fundamental limitation of HLA-A matched humanized mice (mHM), generated with donor hematopoietic stem and progenitor cells and bearing patient-derived xenografts, is that the fidelity of the interaction between the immune system and implanted tumors is limited by lack of thymic T-cell education. We created a model with patient-matched thymic and tumor tissue by using patient peripheral blood mononuclear cells reprogrammed into induced pluripotent stem cells to generate stem cell–derived thymic organoids (sTOs). When implanted in thymectomized mHM, which were subsequently engrafted with patient melanoma tissue (autologous, or mHM TA ), sTOs expressed thymic tissue markers EPCAM, KRT5, and KRT8 and contained developing double-positive T cells. mHM TA had more activated HLA-DR+ T cells in their spleens. Tumor growth in mHM TA was significantly slower compared with mHM, and both tumor volume and viable melanoma content were significantly decreased in mHM TA . This was associated with an increase of intratumoral activated T cells in mHM TA . Whole-exome sequencing followed by intratumoral heterogeneity analysis identified seven candidate neoantigens that were selected against in the mHM TA model, suggesting more effective identification and T cell–driven tumor clearance. This study shows the feasibility of generating patient-specific, thymus-bearing mice and provides a promising new tool in immunology and immunotherapy development. Significance: A humanized mouse xenograft model, in which T cells are educated in a patient-derived implanted thymic organoid autologous to the tumor, provides a more faithful and complete environment to study cancer immunity.
Year:
2025
Changes in intratumoral heterogeneity in mHM TA PDXs can be explained by neoAg selection. A, NeoAg distribution across HLA alleles ( B ) Kullback–Leibler logos show enrichment of hydrophobic amino acids at position 9 in the neoAg pool. The height of each one letter amino acid code is the absolute enrichment relative to unselected peptides. Values above the x axis are positively enriched whereas those below are depleted. C, Distribution of estimated changes in variant allele frequency between the mHM TA and mHM models in all variants identified by exome sequencing. Values to the right of the dotted line represent variants that enriched, or underwent positive selection in mHM TA , whereas values to the left represent variants that underwent negative selection. D, Significant changes between mHM and mHM TA variant allele frequencies are plotted against the predicted HLA binding affinity for nine-mer peptides derived from each variant. The points are colored by which class I HLA molecule the peptide was predicted to bind. All significantly altered variants were found to produce at least two neoAgs. Error bars represent SE. E, Single letter codes for each amino acid are shown with the mutant residue outlined in each. The majority of mutations occurred at TCR contact residue locations (positions 3–8).
Year:
2025
In vitro patient-specific sTO characterization. A, Differentiation of patient-derived iPSCs to TEPs and subsequent production of sTOs. iPSCs are differentiated into TEPs. Coculture of allogeneic (for in vitro examination of the sTOs) or HLA-A –matched HSPCs (for in vivo experiments) at the air–liquid interface produces sTOs with functional TECs. B, qPCR examination of key thymic marker expression in sTOs in vitro . The fold change (2 −ddCt ) in the expression of these genes in sTO cultures at 0-, 3-, and 6-week timepoints was compared with that of undifferentiated iPSCs. Significance was determined using a one-way ANOVA with a Tukey multiple comparison test. cTEC, cortical TEC; mTEC, medullary TEC. C, qPCR examination of tissue-restricted antigen expression in vitro , indicative of AIRE activity, calculated and with significance as determined above. D, IF microscopy of sTOs after 3 weeks of culture shows cell structures expressing thymic markers and identifies presumptive T cells within these structures. DP T cells are indicated by white arrows. Magnification is 40×. Scale bar, 100 μm. E, Cytometry of dissociated sTOs to identify maturing T cells. CD5/7 proT cells were identified after gating CD45 + cells, whereas CD4/8 + T cells were identified after gating CD45 and CD3/TCRαβ cells. P values: *, ≤0.05; **, ≤0.01; *** ≤0.001.
Year:
2025
Examination of T-cell development and activity in the mHM TA . A, Representative cytometry of the human CD45 + cells and HSPCs present in mHM and mHM TA bone marrow. B, Comparison of the average percentage of human CD45 + cells and CD34 + HSPCs within this CD45 + cell population within mHM and mHM TA bone marrow ( P = 0.118 and 0.379, respectively, Wilcoxon rank-sum test). C, Comparison of peripheral human CD45 + lymphocytes in mHM and mHM TA ( P = 0.728, Wilcoxon rank-sum test) and of CD19 + B cells in mHM and mHM TA (0.224, Wilcoxon rank-sum test). D, Cytometric analysis and a comparison of human CD45 + cells, as well as T-cell and B-cell populations, found in the spleens of mHM and mHM TA . E, Comparison of the average human CD45 + cell populations, human T cells, and human B cells on mHM and mHMTA spleens ( P = 0.844, 0.450, and 0.646, Wilcoxon rank-sum test, respectively). F, IFNγ expression was detected in the spleen of both mHM and mHM TA ( P G, Gating and representative cytometry of T cells in mHM and mHM TA show relative populations used to analyze T-cell activation. Purple boxes in the first panels show the T-cell populations gated in the remaining scatter plots. The red boxes show the CD8 + T-cell populations gated for subsequent analysis. H, Representative cytometry of the CD8 + T cells, gated from the red boxes in the previous panel. I, Comparisons of the ratio of HLA-DR + PD1– T cells with all HLA-DR+ T cells shows an increasingly activated T-cell population in mHM TA ( P = 0.0207, two-group t test) and a nonsignificantly increased population of CD4 + T cells. J, Comparison of the HLA-DR + PD1– population with the total HLA-DR+ T-cell population among CD8 + T cells also reveals a trend toward increased activation in mHM TA . P values: *, ≤0.05.
Year:
2025
Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells, leaving patients dependent on exogenous insulin and at risk of severe hypoglycemic episodes. Stem cell-derived beta-like cells (sBCs) offer a promising approach for beta cell replacement therapy, but clinical translation is limited by immune-mediated rejection, recurrent autoimmunity, and inhospitable transplantation sites. Biomaterials have been investigated to provide localized immune-isolation and immunomodulation, but foreign body responses and rapid depletion of therapeutic agents remain as obstacles to clinical translation. Here, we present a microporous annealed particle (MAP) hydrogel functionalized with an anti-CD3 monoclonal antibody (αCD3) to provide a localized immunomodulatory microenvironment for beta cell replacement therapy. MAP hydrogels consisting of guest-host interlinked polyethylene glycol-maleimide (PEG-MAL) microgels supported rapid vascularization, minimal foreign body response, and engraftment of syngeneic islets in mice. αCD3 MAP hydrogel halted T cell migration in vitro and protected transplanted sBCs from immune-mediated destruction by HLA-matched diabetogenic T cells in vivo . Subcutaneous αCD3 functionalized MAP hydrogel also protected the endogenous islets in the pancreas, demonstrating potential for systemic immune modulation. These findings establish αCD3 MAP hydrogels as a promising strategy for localized immune modulation in cell replacement therapy.
Year:
2025
Tissue-targeted immunotherapies for type 1 diabetes (T1D) hold potential to protect pancreatic beta cells while minimizing systemic immunosuppression. We used a bispecific agonist called Immune Modulating Monoclonal-TCR Against Autoimmune Disease (ImmTAAI), consisting of a T cell receptor (TCR) targeting domain fused with a PD-1 agonist to specifically bind beta cells and suppress autoreactive T cells. We used live pancreas slices to demonstrate targeting of ImmTAAI molecules to pre-proinsulin peptide-HLA-A2 complexes on human beta cells. ImmTAAI protected beta cells from T cell killing by increasing T cell motility and inhibiting cytokine secretion. ImmTAAI treatment also increased the motility of islet-infiltrating T cells in slices from a donor with recent-onset T1D and preserved insulin secretion in slices co-cultured with T cell avatars transduced with diabetogenic TCRs. These data demonstrate that ImmTAAI molecules have the potential to limit T cell activity locally, making this an attractive platform to elicit targeted immunoregulation in T1D. One Sentence Summary We demonstrate inhibition of cellular immunity in human type 1 diabetes using a beta cell-targeting, affinity-enhanced TCR fused to a PD-1 agonist.
Year:
2025
Ribosome profiling (Ribo-seq) measures translational regulation and reveals novel or unannotated open reading frames (nuORFs) otherwise difficult to identify. Recent reports demonstrate that nuORFs regulate gene expression and immune recognition, highlighting their emerging biological roles. Pancreatic β-cells are critical for maintaining euglycemic conditions, and β-cell impairment contributes to diabetes development. Identification of nuORF and protein/peptide products in human β-cells could reveal novel mechanisms that regulate β-cell function during homeostatic and disease conditions. Here, we applied a proteogenomic approach to human β-cells to define previously unknown protein/peptide products. First, we applied cell type–specific Ribo-seq to map the translatome of human stem cell–derived β-cells (sBCs). Pathways crucial for β-cell function and antigen presentation were subject to translational regulation. We detected a recently described immunogenic neoantigen, INS-DRiP, presumably originating from a downstream start site in INS mRNA. Moreover, our analysis revealed 965 novel nuORFs in sBCs, with a majority showing protein-level support. Comparison with primary human islets further validated nuORF translation and highlighted β-cell specificity. We identified a novel, primate-specific regulatory upstream ORF within TYK2, which is crucial for β-cell function and interferon response and has many variants strongly associated with type 1 diabetes. Finally, we used immunopeptidomics, HLA-binding prediction models, and T-cell coculture assays to validate the presentation and immunogenicity of preproinsulin peptides and nuORFs. Our findings underscore the importance of translational regulation in β-cell function and provide an important resource to the diabetes research community. Article Highlights We developed a cell type–specific proteogenomic approach to reveal novel or unannotated open reading frames (nuORFs) using transcriptomics, ribosomal profiling, and proteomic analysis of human pancreatic β-cells using stem cell–derived β-cells and/or cadaveric islets. Our analysis revealed translational regulation of β-cell–specific pathways during differentiation and identified 965 nuORFs, with a majority exhibiting protein support and substantial β-cell specificity. A primate-specific ORF located in the 5′ untranslated region of the type 1 diabetes risk gene TYK2 may act as a translational activator. We provide HLA class I immunopeptidomic data from cytokine-stimulated human β-cells and demonstrate their utility in coculture assays with autoreactive T-cell transductants. Taken together, our results define the human β-cell translatome, an important resource to the research field.
Year:
2025
Insulin-producing β-cell replacement therapies offers a potential treatment for type 1 diabetes (T1D) but faces challenges from donor shortages and immune rejection. Stem cell-derived β-cells (sBC) provide a renewable source but remain vulnerable to immune attack. We engineered human pluripotent stem cells to express either the wildtype (WT) or a high-affinity mutant (Mut) variant (rs1058402, G>A; Ala67Thr) of the NK and T cell checkpoint inhibitor CD155 before differentiation into sBC. Modified sBC maintained upregulated CD155 expression and showed enhanced binding to co-receptor ligands. Co-culture studies revealed that CD155 Mut-expressing sBC suppressed CD8 + T cell and NK cell activation and proliferation by preferentially engaging the co-inhibitory receptor TIGIT. Both CD155 Mut sBC lines reduced autoreactive CD8 + T cell- and NK cell-mediated sBC destruction and cytotoxic molecule secretion. This protection was lost with TIGIT blockade, confirming the role of CD155-TIGIT signaling in antagonizing immune cell-mediated killing. Our findings suggest that high-affinity CD155 expression enhances immune evasion of sBC, improving their potential for restorative therapy in T1D. Teaser Engineered β-cells with a mutant CD155 help evade immune attack, offering a promising therapeutic approach for type 1 diabetes.
Year:
2025
Year:
2024
Year:
2023
Collaborators (12)
Carissa Thomas
The University of Alabama
William A. Robinson
Proffessor of Medicine
-
Hussein Al-Mossawi
NIHR Academic Clinical Lecturer
University of Oxford
Mark A. Atkinson
University of Florida
Theresa Medina
Associate Professor
University of Colorado Cancer Center
Todd Brusko
Professor/Scientific Director
University of Florida
Edward Phelps
Associate Professor
University of Florida
Stephen Keysar
Assistant Research Professor
University of Colorado Anschutz Medical Campus
John Morton
Assistant Research Professor
University of Colorado Anschutz Medical Campus
Antonio Jimeno
University of Denver
Neelanjan Mukherjee
Assistant Professor
University of Colorado School of Medicine
Dexiang Gao
Professor
University of Colorado Anschutz Medical Campus
Make your next move.
Prepare your application
Review drafts before you send them.